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This review updates our current knowledge on the mechanism of action of strontium ranelate and analyses the way it rebalances bone
turnover and how it influences bone biomechanics. Strontium ranelate is able to increase pre-osteoblast replication, osteoblast differentiation,
collagen type I synthesis and bone matrix mineralization probably through a calcium-sensing receptor (CaR)-dependent mechanism.
Paralleling this anabolic effect there is inhibition of osteoclast differentiation and activity mediated by an increase in osteoprotegerin (OPG)
and a decrease in RANK ligand (RANKL). The overall effect is a rebalanced bone turnover in favour of improved bone geometry, cortical
thickness, trabecular bone morphology and intrinsic bone tissue quality, which translates into enhanced bone strength.
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Introduction
Bone is composed of cells and an extracellular matrix, mainly
occupied by type I collagen, which confers ductility to bone,
meaning that it allows bone to absorb energy through plastic
deformation, without total failure (fracture) of bone structure
[1, 2]. On the other hand, collagen type I acts as a scaffold for
bone mineralization and directs the deposition of calcium
hydroxyapatite crystals, a critical determinant of bone stiffness
and strength [1, 2]. In fact, the efficacy of bone as a structural
element of our body depends on the balance between these
different bone components and their biomechanical properties.
However, this balance is permanently being challenged by bone
formation and resorption, in a process called bone remodelling,
which is mediated by three distinct cell types: the osteoblasts, or
bone-forming cells, the osteoclasts, or bone-resorbing cells, whose
functions are intimately linked, and the osteocytes, which are
osteoblasts entrapped within bone lacunae [3]. In order to
physiologically balance bone formation and resorption in healthy
individuals, there is a constant cross-talk between these three key
players in bone metabolism [4]. Resorption is much faster than
formation: an area of bone can be resorbed in 2–3 weeks but it
takes at least 3 months to rebuild it [4]. Consequently, when
resorption is increased, such as after menopause, bone formation
is not able to fully compensate this effect and changes in geometry,
cortical thickness, trabecular bone morphology and intrinsic bone
tissue quality occur, causing degradation of bone biomechanical
properties. Ideally, to reverse this process, treatments should be
able to rebalance bone remodelling, providing bone with adequate
amounts of organic and mineralized matrix in order to restore
bone biomechanical properties.
Strontium ranelate is a treatment of osteoporosis which, unlike
any other drug, has a dual effect on bone remodelling, being able
to stimulate bone formation by osteoblasts, a property shared
with bone-forming agents, and to inhibit bone resorption by
osteoclasts, as do anti-resorptive agents [5]. Strontium ranelate is
composed of two atoms of stable strontium (Sr) combined with
ranelic acid, which acts as carrier [6].
This review will update our current knowledge on the
mechanism of action of strontium ranelate and will analyse to
what extent this drug is able to rebalance bone turnover and to
restore biomechanics in osteoporotic bone.
Pre-osteoblast replication, osteoblast differentiation,
collagen synthesis and matrix mineralization
In rat calvarial cultures, strontium ranelate enhances the replica-
tion of pre-osteoblasts and increases collagen type I synthesis [7].
In addition, in primary osteoblasts derived from mouse calvaria,
strontium ranelate promotes bone nodule formation, increasing
the differentiation from early progenitor cells to mature osteo-
blasts, as reflected by the expression of osteoblastic markers such
as ALP, bone sialoprotein and OC [8]. Moreover, bone marrow
stromal cells, exposed to a differentiating medium for 21 days,
when treated with strontium ranelate showed an increase in the
formation of mineralized colony-forming unit-osteoblasts and in
the expression of the Runx2 gene, but not of OC [9]. On the
contrary, in more mature osteoblastic OB-6 cells strontium
ranelate induced only minimal effects on Runx2 expression but
had a positive effect on OC expression [9]. Runx2 is a master gene
so critical for osteoblast differentiation that mice deficient in this
gene fail to form osteoblasts [10], while OC is a known negative
regulator of osteoblast differentiation, normally expressed during
the latter stages of differentiation [11]. From these experiments it
can be concluded that strontium ranelate stimulates the replica-
tion of pre-osteoblast, increases collagen type I production and
induces the differentiation of the osteoblast into a more mature,
mineralizing phenotype. For the appropriate clinical interpreta-
tion of these conclusions it is important to highlight that most of
these effects occur with a concentration of strontium ranelate as
low as 0.1mM, which is close to the active concentration in the
blood of post-menopausal osteoporotic women treated with
strontium ranelate (0.12nM) [8, 12].
Despite our current knowledge on the cellular effects of
strontium ranelate on osteoblasts, the precise molecular mechan-
isms involved remain elusive. Since Sr is a divalent cation that
closely resembles Ca in its atomic and ionic properties, it has been
hypothesized that strontium ranelate could act as an agonist of the
extracellular Ca-sensing receptor (CaR) that is expressed at all
stages of osteoblast development and exerts several actions on
bone cells in vitro that could be the basis for the known anabolic
effects of Ca in bone [13, 14]. Indeed, preliminary data have
demonstrated that strontium ranelate activates CaR [15]. It was
shown more recently in human embryonic kidney 293 (HEK293)
cells transfected with bovine CaR (HEK–CaR) that Ca and
strontium ranelate concentration-dependently activated the CaR,
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induced further CaR activation [16]. Interestingly, strontium
ranelate was less potent than Ca in stimulating inositol
phosphate accumulation but was comparable with Ca in stim-
ulating extracellular signal-regulated kinase (ERK) phosphoryla-
tion and a non-selective cation channel, suggesting that Ca and
strontium ranelate have differential cellular effects [16].
Reinforcing the existence of at least partially separate molecular
mechanisms from Ca, strontium ranelate activation of mitogen-
activated protein (MAP) kinase and protein kinase C (PKC)
pathways is delayed in comparison with activation mediated by
CaCl2, possibly due to the synthesis of an autocrine growth factor,
and its proliferative effect on osteoblasts appears to be mainly
dependent on PKC but not on MAP kinases [17]. Finally, rat
primary osteoblasts proliferation and the expression of genes
involved in osteoblast proliferation and differentiation, such as
c-Fos and Egr-1, were shown to be stimulated by strontium
ranelate, but the effect was attenuated by overexpressing the
dominant negative CaR, demonstrating that the mechanism was
CaR-mediated [16]. Therefore, strontium ranelate is a full CaR
agonist in primary osteoblasts and its proliferative effect on these
cells can be, at least partially, explained by a CaR-dependent
mechanism. Nevertheless, the strontium ranelate concentration
needed to attain this effect was higher than that measured in
patients treated with 2g of strontium ranelate per day [12].
Despite the lack of direct evidence, it has been hypothesized that
only CaR expressed at sites where the levels of either Ca or
strontium ranelate might be higher than in blood, such as bone,
would be stimulated by therapeutic doses of strontium ranelate,
thus not affecting CaR in peripheral tissues, such as kidney and
parathyroid [16].
Overall, the data presented so far suggest that strontium
ranelate induces pre-osteoblast proliferation, enhances osteoblast
differentiation and activity, leading to collagen type I synthesis
and mineralization, through molecular mechanisms possibly
involving CaR activation.
RANK ligand/osteoprotegerin ratio
One of the key elements in the cross-talk between osteoblasts and
osteoclasts is the RANK ligand (RANKL) and osteoprotegerin
(OPG) system. RANKL, expressed by pre-osteoblasts and
osteoblasts, activates its receptor RANK, present on pre-
osteoclasts and osteoclasts, inducing the differentiation of
mature osteoclasts and increasing osteoclast survival [18]. OPG,
a soluble receptor for RANKL produced by osteoblasts, inhibits
RANKL-induced osteoclastogenesis [18]. Thus, the OPG/
RANKL ratio is decisive for bone resorption and a decreased
ratio has been described in clinical settings where bone loss occurs,
such as in post-menopausal women. On the contrary, drugs that
could increase this ratio would contribute to a reduction in
bone resorption. Interestingly, strontium ranelate enhances
OPG expression and down-regulates RANKL expression both
in primary human osteoblastic cells in vitro and in murine rat
calvaria cells, [19]. These observations could mean that when
strontium ranelate stimulates osteoblasts two types of signals are
produced simultaneously: anabolic pathways are activated in pre-
osteoblasts and osteoblasts, and an anti-catabolic message is sent
to pre-osteoclasts and osteoclasts throughout an increase in the
OPG/RANKL ratio.
Osteoclast differentiation, activity and apoptosis
Apart from possible interference with the OPG/RANKL system,
strontium ranelate has been shown to interfere directly with
osteoclasts. As a matter of fact, strontium ranelate was able to
decrease osteoclast markers in differentiating chicken bone
marrow cultures and murine osteoclasts, to reduce bone resorp-
tion in mouse organ cultures of cranial bone and mouse
osteoclasts, to diminish differentiation of human monocyte into
osteoclast and to enhance osteoclast apoptosis [20–22]. These
observations were recently confirmed in osteoclasts derived from
murine spleen cells in a series of experiments where the number of
mature osteoclasts and their resorbing activity were strongly
decreased after strontium ranelate exposure, in a process asso-
ciated with the disruption of the actin cytoskeleton of the
osteoclast-sealing zone [8]. As the CaR is directly involved in
both osteoclast differentiation and apoptosis [23] and strontium
ranelate is able to stimulate this receptor [15, 16] it seems likely
that stimulation of CaR is the underlying major mechanism
for the cellular effects of strontium ranelate on these cells.
Accordingly, there is preliminary evidence for a CaR-mediated
strontium ranelate-induced osteoclast apoptosis [24].
Taken together these results indicate that strontium ranelate is
able to decrease osteoclast differentiation and activity and enhance
osteoclast apoptosis through a CaR-dependent mechanism.
Bone structure and biomechanics
Strontium ranelate has been studied in various rat and animal
models, including intact animals, immobilization-induced osteo-
penia and ovariectomy-induced osteoporosis [25–29]. In these
in vivo experiments, strontium ranelate increased markers of bone
formation and decreased markers of bone resorption, promoting
bone gain as reflected in increased external diameter of long
bones, enhanced bone mass evaluated by DXA and microarch-
itecture improvement assessed by histomorphometry [25–29].
These observations are in accordance with the results of strontium
ranelate in clinical trials that have shown an uncoupling of bone
markers, increase in DXA results [12] and histomorphometric
bone improvement [30]. Furthermore, these positive effects on
bone were obtained without affecting bone mineralization [31].
The bone gain induced by strontium ranelate treatment was
predictive of increased bone strength that was indirectly con-
firmed by the reduction in fracture risk in clinical trials [12, 32]
and directly documented in a series of animal experiments. In
effect, the occurrence of fractures is a multifactor event and only
animal models provide objective information on all the structural
determinants of bone strength: bone geometry, cortical thickness
and porosity, trabecular bone morphology and intrinsic properties
of bone tissue [33]. The first set of experiments was performed in
intact female rats [25] treated over a 2-yr period with doses that
reached plasma levels close to the value observed in patients
treated with 2g/day [12]. In the strontium ranelate group, there
was an increase in the external diameter and cortical thickness of
long bones, as well as an improvement in vertebral bone mass,
trabecular bone volume, trabeculae number, trabecular thickness,
connectivity and cortical thickness, reflecting improved bone
geometry, cortical properties, porosity and trabecular bone
morphology [25]. Moreover, 3-point bending tests performed on
the mid-shaft femur reveal a dose-dependent increase in maximal
load and total energy without modification of bone stiffness, while
L4 vertebral body compression tests produced similar results, with
most of the energy being absorbed at the cost of an increase in
plastic, but not elastic energy [25]. Consequently, new bone
formed following strontium ranelate treatment is able to with-
stand greater deformation before fracture (increased ductility),
while keeping normal bone elastic properties. A subsequent study
analysed the biomechanical effects of strontium ranelate in a
setting closer to clinical practice. Six-month-old ovariectomized
rats treated over a 1-yr period with strontium ranelate showed
dose-dependent prevention of bone strength alteration, but only
partial prevention of microarchitecture bone changes, suggesting
that direct effects on intrinsic bone quality might be an additional
explanation for the improvement in bone strength in mature rats
[34]. In addition, some of the strontium ranelate may be absorbed
in the hydrated bone layer, as suggested by the fact that it is
rapidly eliminated after treatment withdrawal, potentially
iv18 J. E. Fonsecaallowing it to influence intrinsic bone tissue quality [35]. To test
this hypothesis, nanoindentation tests were performed on
trabecular bone and cortex in vertebrae of rats treated with
several different doses of strontium ranelate [36]. In agreement
with previous results, strontium ranelate increased maximal load,
total energy and plastic energy, and enhanced elastic modulus,
hardness and dissipated energy in trabecular bone, but these
effects were only present in wet conditions [36]. These effects
totally disappeared in dry conditions suggesting that the presence
of strontium ranelate in the hydrated bone layer could structurally
modify the bone matrix and directly improve intrinsic bone tissue
quality, and thus potentially decrease the propagation of
microcracks and enhance bone strength [36].
Altogether, structural and biomechanical results have shown
that strontium ranelate is able to positively influence bone
geometry, cortical thickness and porosity, trabecular bone
morphology and intrinsic bone tissue quality, globally resulting
in increased bone strength.
Conclusion
We have seen that strontium ranelate is able to increase pre-
osteoblast replication, osteoblast differentiation, collagen type I
synthesis and bone matrix mineralization probably through a
CaR-dependent mechanism. Paralleling these anabolic effects,
there is inhibition of osteoclast differentiation and activity and
enhanced osteoclast apoptosis apparently mediated by an increase
in OPG/RANKL ratio and by a CaR-mediated mechanism. The
overall effect is a rebalanced bone turnover in favour of improved
bone geometry, cortical thickness, trabecular bone morphology
and intrinsic bone tissue quality, which translates into enhanced
bone strength.
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Rheumatology key messages
 Strontium ranelate induces pre-osteoblast replication, osteoblast
differentiation, collagen type I synthesis and bone matrix
mineralization.
 Strontium ranelate inhibits osteoclast differentiation through an
increase in OPG and a decrease in RANKL.
 Strontium ranelate rebalances bone turnover in favour of
enhanced bone strength.
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